Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials

BACKGROUND: Ramucirumab is a widely used cancer drug having gained six regulatory approvals in various advanced solid tumors. Thus, assessing the risk-benefit profile of such a commonly used drug across multiple tumor types is necessary to inform clinical and reimbursement decisions. To objectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Effing, Sophie Marie Anne, Gyawali, Bishal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486320/
https://www.ncbi.nlm.nih.gov/pubmed/32954236
http://dx.doi.org/10.1016/j.eclinm.2020.100458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486320/
https://www.ncbi.nlm.nih.gov/pubmed/32954236
http://dx.doi.org/10.1016/j.eclinm.2020.100458

Ejemplares similares